Fitness to drive and cannabis: Validation of two blood THCCOOH thresholds to distinguish occasional users from heavy smokers

Forensic Science International

Volumn 242, Issue , 2014, Pages 1-8

  Fabritius, Marie ^a   Augsburger, Marc ^a   Chtioui, Haithem ^b   Favrat, Bernard ^a   Giroud, Christian ^a  

^a UNIVERSITY CENTER OF LEGAL MEDICINE   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Cannabis; Heavy use; Occasional use; THCCOOH; Whole blood

Indexed keywords

TETRAHYDROCANNABINOLIC ACID; 11-NOR-DELTA(9)-TETRAHYDROCANNABINOL-9-CARBOXYLIC ACID; DRONABINOL;

ADOLESCENT; ADULT; ARTICLE; BLOOD LEVEL; CANNABIS SMOKING; CANNABIS USE; CONTROLLED STUDY; DRIVING ABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; OFFENDER; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SWITZERLAND; TRAFFIC SAFETY; VALIDITY; ANALOGS AND DERIVATIVES; BLOOD; CAR DRIVING; LEGISLATION AND JURISPRUDENCE; MARIJUANA ABUSE; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AUTOMOBILE DRIVING; DRONABINOL; HUMANS; MALE; MARIJUANA ABUSE; MARIJUANA SMOKING; MIDDLE AGED; ROC CURVE; YOUNG ADULT;

EID: 84903840406     PISSN: 03790738     EISSN: 18726283     Source Type: Journal    
DOI: 10.1016/j.forsciint.2014.05.014     Document Type: Article

References (54)

1. World_Health_Organization. World report on road traffic injury prevention. 2014:1-244 (accessed 14.01.13). http://whqlibdoc.who.int/publications/2004/9241562609.pdf.
2. Augsburger M., Donze N., Menetrey A., Brossard C., Sporkert F., Giroud C., et al. Concentration of drugs in blood of suspected impaired drivers. Forensic Sci. Int. 2005, 153(1):11-15.
3. Senna M.C., Augsburger M., Aebi B., Briellmann T.A., Donze N., Dubugnon J.L., et al. First nationwide study on driving under the influence of drugs in Switzerland. Forensic Sci. Int. 2010, 198(1-3):11-16.
4. Johnson M.B., Kelley-Baker T., Voas R.B., Lacey J.H. The prevalence of cannabis-involved driving in California. Drug Alcohol Depend. 2012, 123(1-3):105-109.
5. Asbridge M., Hayden J.A., Cartwright J.L. Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. BMJ 2012, 344:e536.
6. Hels T., Lyckegaard A., Simonsen K.W., Steentoft A., Bernhoft I.M. Risk of severe driver injury by driving with psychoactive substances. Accid. Anal. Prev. 2013, 59:346-356.
7. Elvik R. Risk of road accident associated with the use of drugs: a systematic review and meta-analysis of evidence from epidemiological studies. Accid. Anal. Prev. 2013, 60:254-267.
8. Menetrey A., Augsburger M., Favrat B., Pin M.A., Rothuizen L.E., Appenzeller M., et al. Assessment of driving capability through the use of clinical and psychomotor tests in relation to blood cannabinoids levels following oral administration of 20mg dronabinol or of a cannabis decoction made with 20 or 60mg Delta9-THC. J. Anal. Toxicol. 2005, 29(5):327-338.
9. Battistella G., Fornari E., Thomas A., Mall J.F., Chtioui H., Appenzeller M., et al. Weed or wheel! FMRI, behavioural, and toxicological investigations of how cannabis smoking affects skills necessary for driving. PLoS One 2013, 8(1):e52545.
10. Ramaekers J.G., Kauert G., Theunissen E.L., Toennes S.W., Moeller M.R. Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. J. Psychopharmacol. 2009, 23(3):266-277.
11. Crean R.D., Crane N.A., Mason B.J. An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. J. Addict. Med. 2011, 5(1):1-8.
12. Bosker W.M., Karschner E.L., Lee D., Goodwin R.S., Hirvonen J., Innis R.B., et al. Psychomotor function in chronic daily cannabis smokers during sustained abstinence. PLoS One 2013, 8(1):e53127.
13. Sewell R.A., Poling J., Sofuoglu M. The effect of cannabis compared with alcohol on driving. Am. J. Addict. 2009, 18(3):185-193.
14. Hartman R.L., Huestis M.A. Cannabis effects on driving skills. Clin. Chem. 2013, 59(3):478-492.
15. Armentano P. Cannabis and psychomotor performance: a rational review of the evidence and implications for public policy. Drug Test. Anal. 2013, 5(1):52-56.
16. Redelmeier D.A., Yarnell C.J., Thiruchelvam D., Tibshirani R.J. Physicians' warnings for unfit drivers and the risk of trauma from road crashes. N. Eng. J. Med. 2012, 367(13):1228-1236.
17. Ramaekers J.G., Moeller M.R., van Ruitenbeek P., Theunissen E.L., Schneider E., Kauert G. Cognition and motor control as a function of Delta9-THC concentration in serum and oral fluid: limits of impairment. Drug Alcohol Depend. 2006, 85(2):114-122.
18. Schwope D.M., Bosker W.M., Ramaekers J.G., Gorelick D.A., Huestis M.A. Psychomotor performance, subjective and physiological effects and whole blood Delta(9)-tetrahydrocannabinol concentrations in heavy, chronic cannabis smokers following acute smoked cannabis. J. Anal. Toxicol. 2012, 36(6):405-412.
19. D'Souza D.C., Ranganathan M., Braley G., Gueorguieva R., Zimolo Z., Cooper T., et al. Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology 2008, 33(10):2505-2516.
20. van Wel J.H., Kuypers K.P., Theunissen E.L., Toennes S.W., Spronk D.B., Verkes R.J., et al. Single doses of THC and cocaine decrease proficiency of impulse control in heavy cannabis users. Br. J. Pharmacol. 2013, 170(7):1410-1420.
21. Richer I., Bergeron J. Driving under the influence of cannabis: links with dangerous driving, psychological predictors, and accident involvement. Accid. Anal. Prev. 2009, 41(2):299-307.
22. Bosker W.M., Kuypers K.P., Theunissen E.L., Surinx A., Blankespoor R.J., Skopp G., et al. Medicinal Delta(9)-tetrahydrocannabinol (dronabinol) impairs on-the-road driving performance of occasional and heavy cannabis users but is not detected in Standard Field Sobriety Tests. Addiction 2012, 107(10):1837-1844.
23. Blows S., Ivers R.Q., Connor J., Ameratunga S., Woodward M., Norton R. Marijuana use and car crash injury. Addiction 2005, 100(5):605-611.
24. Battistella G., Fornari E., Annoni J.M., Chtioui H., Dao K., Fabritius M., et al. Long-term effects of cannabis on brain structure. Neuropsychopharmacology 2014.
25. Briellmann T.A., Sigrist T., Augsburger M., Favrat B., Oestreich A., Deom A. Quality assurance in road traffic analyses in Switzerland. Forensic Sci. Int. 2010, 198(1-3):7-10.
26. Baumgartner M.R., Guglielmello R., Fanger M., Kraemer T. Analysis of drugs of abuse in hair: evaluation of the immunochemical method VMA-T vs. LC-MS/MS or GC-MS. Forensic Sci. Int. 2012, 215(1-3):56-59.
27. Fabritius M., Favrat B., Chtioui H., Battistella G., Annoni J.M., Appenzeller M., et al. THCCOOH concentrations in whole blood: are they useful in discriminating occasional from heavy smokers?. Drug Test. Anal. 2013.
28. Kintz P., Bernhard W., Villain M., Gasser M., Aebi B., Cirimele V. Detection of cannabis use in drivers with the drugwipe device and by GC-MS after intercept device collection. J. Anal. Toxicol. 2005, 29(7):724-727.
29. Adamson S.J., Kay-Lambkin F.J., Baker A.L., Lewin T.J., Thornton L., Kelly B.J., et al. An improved brief measure of cannabis misuse: the Cannabis Use Disorders Identification Test-Revised (CUDIT-R). Drug Alcohol. Depend. 2010, 110(1-2):137-143.
30. Legleye S., Piontek D., Kraus L., Morand E., Falissard B. A validation of the Cannabis Abuse Screening Test (CAST) using a latent class analysis of the DSM-IV among adolescents. Int. J. Methods Psychiatr. Res. 2013, 22(1):16-26.
31. Legleye S., Karila L., Beck F., Reynaud M. Validation of the CAST, a general population Cannabis Abuse Screening Test. J. Subst. Use 2007, 12(4):233-242.
32. Fabritius M., Chtioui H., Battistella G., Annoni J.M., Dao K., Favrat B., et al. Comparison of cannabinoid concentrations in oral fluid and whole blood between occasional and regular cannabis smokers prior to and after smoking a cannabis joint. Anal. Bioanal. Chem. 2013, 405(30):9791-9803.
33. Thomas A., Widmer C., Hopfgartner G., Staub C. Fast gas chromatography and negative-ion chemical ionization tandem mass spectrometry for forensic analysis of cannabinoids in whole blood. J. Pharm. Biomed. Anal. 2007, 45(3):495-503.
34. Swiss-Federal-Roads-Office-(FEDRO). Instructions regarding the diagnosis of inability to drive. 2014:1-35 (accessed 10.04.14). http://05-22_2362_f.pdf.
35. Huestis M.A., Henningfield J.E., Cone E.J. Blood cannabinoids. II. Models for the prediction of time of marijuana exposure from plasma concentrations of delta 9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-delta 9-tetrahydrocannabinol (THCCOOH). J. Anal. Toxicol. 1992, 16(5):283-290.
36. Swiss_Society_of_Forensic_Medicine. Drugs and driving in Switzerland review of drug concentrations in blood and urine from drivers suspected of driving under the influence of narcotics, alcohol and/or of therapeutic drugs from 2005 to 2007. 2014:1-88 (accessed 11.04.2014). http://www.sgrm.ch/uploads/media/Rapport_Final_MDV_OFSP_01.pdf.
37. Niemela O. Biomarkers in alcoholism. Clin. Chim. Acta 2007, 377(1-2):39-49.
38. Bland T.M., Haining R.L., Tracy T.S., Callery P.S. CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin. Biochem. Pharmacol. 2005, 70(7):1096-1103.
39. Toennes S.W., Schneider K., Kauert G.F., Wunder C., Moeller M.R., Theunissen E.L., et al. Influence of ethanol on cannabinoid pharmacokinetic parameters in chronic users. Anal. Bioanal. Chem. 2011, 400(1):145-152.
40. Giroud C., Menetrey A., Augsburger M., Buclin T., Sanchez-Mazas P., Mangin P. Delta(9)-THC, 11-OH-Delta(9)-THC and Delta(9)-THCCOOH plasma or serum to whole blood concentrations distribution ratios in blood samples taken from living and dead people. Forensic Sci. Int. 2001, 123(2-3):159-164.
41. Karschner E.L., Schwope D.M., Schwilke E.W., Goodwin R.S., Kelly D.L., Gorelick D.A., et al. Predictive model accuracy in estimating last Delta9-tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC. Drug Alcohol. Depend. 2012, 125(3):313-319.
42. Bortolotti F., De Paoli G., Tagliaro F. Carbohydrate-deficient transferrin (CDT) as a marker of alcohol abuse: a critical review of the literature 2001-2005. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 2006, 841(1-2):96-109.
43. Dietz L., Glaz-Sandberg A., Nguyen H., Skopp G., Mikus G., Aderjan R. The urinary disposition of intravenously administered 11-nor-9-carboxy-delta-9-tetrahydrocannabinol in humans. Ther. Drug Monit. 2007, 29(3):368-372.
44. Glaz-Sandberg A., Dietz L., Nguyen H., Oberwittler H., Aderjan R., Mikus G. Pharmacokinetics of 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (CTHC) after intravenous administration of CTHC in healthy human subjects. Clin. Pharmacol. Ther. 2007, 82(1):63-69.
45. Toennes S.W., Ramaekers J.G., Theunissen E.L., Moeller M.R., Kauert G.F. Comparison of cannabinoid pharmacokinetic properties in occasional and heavy users smoking a marijuana or placebo joint. J. Anal. Toxicol. 2008, 32(7):470-477.
46. Strougo A., Zuurman L., Roy C., Pinquier J.L., van Gerven J.M., Cohen A.F., et al. Modelling of the concentration - effect relationship of THC on central nervous system parameters and heart rate - insight into its mechanisms of action and a tool for clinical research and development of cannabinoids. J. Psychopharmacol. 2008, 22(7):717-726.
47. Giroud C., Favrat B., Thomas A.G.B., Mall J.F., Appenzeller M., et al. Blood cannabinoids levels and effects on cognitive performance and behaviour as a function of joint smoking procedure and inhalation technique. Annual Meeting, Society of Forensic Toxicologists 2009, Book of abstracts:S12.
48. Société_Française_de_Toxicologie_Analytique. Consensus cannabis of the French society of analytical toxicology. 2014 (accessed 14.01.2014). http://sfta.org/presentation/main/consensus/Consensus%20cannabis%202013.pdf.
49. Huestis M.A., Cone E.J. Differentiating new marijuana use from residual drug excretion in occasional marijuana users. J. Anal. Toxicol. 1998, 22(6):445-454.
50. Himes S.K., Scheidweiler K.B., Beck O., Gorelick D.A., Desrosiers N.A., Huestis M.A. Cannabinoids in exhaled breath following controlled administration of smoked cannabis. Clin. Chem. 2013, 59(12):1780-1789.
51. Anizan S., Milman G., Desrosiers N., Barnes A.J., Gorelick D.A., Huestis M.A. Oral fluid cannabinoid concentrations following controlled smoked cannabis in chronic frequent and occasional smokers. Anal. Bioanal. Chem. 2013, 405(26):8451-8461.
52. M.-L. Tovar, O. Le Nezet, S. Spilka, A. Cadet-Taïrou, National report (2012 data) to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), France, New developments, trends and in-depth information on selected issues. EMCDDA annual report. 2013 (accessed 14.01.2014). http://www.ofdt.fr/BDD/publications/docs/efnaoftb.pdf.
53. F. Beck, S. Legleye, Drogues et adolescence Usages de drogues et contexte d'usage entre 17 et 19 ans, évolutions récentes, ESCAPAD 2002. ESCAPAD survey. 2014 (accessed 14.01.2014). http://www.ofdt.fr/BDD/publications/docs/epfxfbja.pdf.
54. Han E., Chung H., Song J.M. Segmental hair analysis for 11-nor-Delta(9)-tetrahydrocannabinol-9-carboxylic acid and the patterns of cannabis use. J. Anal. Toxicol. 2012, 36(3):195-200.